Investors Sell C.R. Bard (BCR) on Strength (BCR)

Traders sold shares of C.R. Bard, Inc. (NYSE:BCR) on strength during trading on Tuesday. $14.73 million flowed into the stock on the tick-up and $78.92 million flowed out of the stock on the tick-down, for a money net flow of $64.19 million out of the stock. Of all stocks tracked, C.R. Bard had the 23rd highest net out-flow for the day. C.R. Bard traded up $0.03 for the day and closed at $332.09

Several equities analysts have weighed in on BCR shares. Jefferies Group reaffirmed a “hold” rating and set a $317.00 target price on shares of C.R. Bard in a research note on Thursday, September 14th. Needham & Company LLC reaffirmed a “hold” rating on shares of C.R. Bard in a research note on Thursday, October 26th. Cowen reaffirmed a “hold” rating and set a $317.00 target price on shares of C.R. Bard in a research note on Friday, November 3rd. Barclays lifted their target price on C.R. Bard from $245.00 to $337.00 and gave the company an “equal weight” rating in a research note on Monday, November 6th. Finally, ValuEngine cut C.R. Bard from a “buy” rating to a “hold” rating in a research note on Friday, December 1st. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and one has issued a strong buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $303.50.

The stock has a market cap of $24,263.68, a price-to-earnings ratio of 28.75, a PEG ratio of 2.55 and a beta of 0.52. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.37 and a current ratio of 1.72.

C.R. Bard (NYSE:BCR) last announced its quarterly earnings results on Wednesday, October 25th. The medical instruments supplier reported $3.02 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.96 by $0.06. The business had revenue of $989.80 million during the quarter, compared to analyst estimates of $990.64 million. C.R. Bard had a return on equity of 48.28% and a net margin of 14.75%. The firm’s revenue was up 5.1% on a year-over-year basis. During the same period in the previous year, the company earned $2.64 EPS. analysts anticipate that C.R. Bard, Inc. will post 11.89 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Friday, December 29th. Stockholders of record on Friday, December 8th will be issued a dividend of $0.26 per share. The ex-dividend date is Thursday, December 7th. This represents a $1.04 annualized dividend and a dividend yield of 0.31%. C.R. Bard’s dividend payout ratio is 13.70%.

In related news, insider Christopher S. Holland sold 38,242 shares of the business’s stock in a transaction that occurred on Thursday, November 2nd. The stock was sold at an average price of $334.04, for a total value of $12,774,357.68. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Betty D. Larson sold 5,906 shares of the business’s stock in a transaction that occurred on Friday, October 20th. The stock was sold at an average price of $330.16, for a total value of $1,949,924.96. Following the completion of the sale, the vice president now owns 10,753 shares of the company’s stock, valued at $3,550,210.48. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 191,593 shares of company stock valued at $62,655,513. 0.80% of the stock is owned by corporate insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Farallon Capital Management LLC acquired a new stake in C.R. Bard in the 2nd quarter worth approximately $463,101,000. Renaissance Technologies LLC lifted its holdings in C.R. Bard by 35.4% in the 2nd quarter. Renaissance Technologies LLC now owns 1,295,600 shares of the medical instruments supplier’s stock worth $409,552,000 after purchasing an additional 338,900 shares during the last quarter. Alpine Associates Management Inc. lifted its holdings in C.R. Bard by 10.0% in the 3rd quarter. Alpine Associates Management Inc. now owns 924,263 shares of the medical instruments supplier’s stock worth $296,226,000 after purchasing an additional 83,851 shares during the last quarter. Wells Fargo & Company MN lifted its holdings in C.R. Bard by 32.8% in the 3rd quarter. Wells Fargo & Company MN now owns 775,683 shares of the medical instruments supplier’s stock worth $248,607,000 after purchasing an additional 191,443 shares during the last quarter. Finally, Westchester Capital Management LLC lifted its holdings in C.R. Bard by 14.6% in the 3rd quarter. Westchester Capital Management LLC now owns 575,106 shares of the medical instruments supplier’s stock worth $184,321,000 after purchasing an additional 73,478 shares during the last quarter. Hedge funds and other institutional investors own 79.35% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Investors Sell C.R. Bard (BCR) on Strength (BCR)” was first published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this article on another domain, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The correct version of this article can be read at https://www.chaffeybreeze.com/2017/12/12/investors-sell-c-r-bard-bcr-on-strength-bcr-2.html.

C.R. Bard Company Profile

C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.

Receive News & Ratings for C.R. Bard Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply